Search for: "Genentech, Inc."
Results 121 - 140
of 469
Sort by Relevance
|
Sort by Date
7 Mar 2016, 1:55 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences.Never too late 83 [week ending on Sunday 14 February] – Indigenous IP | Arnold J's latest judgment flags down the iconic London black cab | Life of a national/EU trade mark ... in a map | A comprehensive… [read post]
29 Feb 2016, 11:27 pm
**********PREVIOUSLY, ON NEVER TOO LATENever too late 84 [week ending on Sunday 21 February] – Domain Name Law and Practice | Unwired Planet v Huawei and Samsung | In memoriam of Justice Antonin Scalia | Celltrion Inc. v Biogen Idec Inc., F. [read post]
26 Feb 2016, 1:21 pm
Genentech, Inc., 549 U.S. 118 (2007), decided 8-1 with only Justice Thomas dissenting: the Court decided that the case or controversy requirement of the Constitution did not require a licensee to breach a license agreement in order to challenge the validity of a patent. [read post]
23 Feb 2016, 1:53 am
Hoffmann-La Roche AG and Genentech Inc. [read post]
18 Feb 2016, 3:11 pm
Steve Juelsgaard, former executive vice president of Genentech, also raised questions. [read post]
17 Feb 2016, 12:19 am
Hoffmann-La Roche AG and Genentech Inc. [2016] EWHC 188 (Pat) come across her desk a few weeks ago. [read post]
27 Jan 2016, 8:12 am
Genentech, Inc., 2012 WL 956192 (S.D. [read post]
13 Dec 2015, 7:55 am
. = = = = = [1] Halo Electronics, Inc. v. [read post]
9 Nov 2015, 7:39 am
One of the great advantages of bifurcated patent litigation [perhaps the only advantage, wonders Merpel] is that bifurcated decisions make for shorter judgments and shorter blogposts to explain them. [read post]
6 Nov 2015, 6:58 am
Therefore, it was not obvious to test pregabalin – it might be obvious to test gabapentin, but even here the judge considered that the skilled team would have little expectation of success.InsufficiencyAccording to the caselaw relating to sufficiency developed in MedImmune Ltd v Novartis Pharmaceuticals UK Ltd [2011] EWHC 1699 (Pat) at [458]-[484] and summarised in Sandvik Intellectual Property AB v Kennametal UK Ltd [2011] EWHC 3311 (Pat) at [121]-[124], also set out in… [read post]
25 Oct 2015, 1:40 pm
Nike, Inc., 133 S. [read post]
22 Oct 2015, 8:42 am
IMS Health, Inc., 131 S. [read post]
5 Oct 2015, 6:43 am
Genentech, Inc., the Court relied on its broader declaratory judgement jurisprudence to reject the Federal Circuit’s patent-specific rules. [read post]
8 Sep 2015, 6:40 am
Genentech, Inc. [read post]
2 Aug 2015, 4:01 pm
| Pro-Football Inc v Amanda Blackhorse et al. [read post]
27 Jul 2015, 9:35 am
| Pro-Football Inc v Amanda Blackhorse et al. [read post]
20 Jul 2015, 2:43 am
| Pro-Football Inc v Amanda Blackhorse et al. [read post]
13 Jul 2015, 3:51 am
| Plant variety in Case C‑242/14 | US Supreme Court on spiderman patent | Hospira v Genentech saga | Are EU policy-makers fighting the right copyright battles? [read post]
6 Jul 2015, 12:36 pm
In this episode (Hospira UK Ltd v Genentech Inc [2015] EWHC 1796 (Pat)), Hospira is seeking to invalidate all of Genentech's secondary patents relating to the cancer drug trastuzumab (Herceptin) so that it can market a generic version now that the SPC for the basic patent has expired.* Are EU policy-makers fighting the right copyright battles? [read post]
5 Jul 2015, 12:59 pm
Among the commercial participants, Genentech Inc. spent the most on general payments (that is, not for research), $387.7 million, mostly royalties for its cancer drugs Rituxan, Avastin and Herceptin to City of Hope National Medical Center in Duarte, Calif., a major cancer center. [read post]
